TAO Synergies (TAOX) Change in Account Payables (2019 - 2026)
TAO Synergies' (TAOX) quarterly Change in Account Payables came in at -$47152.0 in Q2 2026, down 122.81% on a YoY basis from $206715.0 in Q2 2025, and up 79.41% quarter-over-quarter from -$228996.0 in Q1 2026.
Analysis
TAO Synergies (TAOX) Change in Account Payables (2019 - 2026) Analysis & Trends
TAO Synergies (TAOX) has reported Change in Account Payables for 8 consecutive years, with -$47152.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Change in Account Payables fell 122.81% year-over-year to -$47152.0; the trailing twelve-month figure through Jun 2026 stood at $578279.0 (up 474.45% YoY), and the FY2025 full-year result was $858036.0, up 773.78% from the prior year.
- Change in Account Payables advanced to -$47152.0 in Q2 2026 per TAOX's latest filing, from -$228996.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $628754.0 in Q3 2025 and bottomed at -$895156.0 in Q1 2022.
- Historically, Change in Account Payables has averaged -$22073.9 across 5 years, with a median of -$8107.5 in 2024.
- The sharpest annual moves came in 2023 and 2025: Change in Account Payables slumped 211.06% in 2023, then jumped 629.46% in 2025.
- Over 5 years, Change in Account Payables stood at $176816.0 in 2022, then soared by 30.31% to $230415.0 in 2023, then sank by 86.57% to $30937.0 in 2024, then surged by 629.46% to $225673.0 in 2025, then sank by 120.89% to -$47152.0 in 2026.
- According to Business Quant data, Change in Account Payables over the past three periods registered -$47152.0, -$228996.0, and $225673.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.37 Bn | 197.38 Bn | 7.24 Bn | -70.00 Mn |
| 2 | Gilead Sciences | 181.12 Bn | 177.94 Bn | 6.22 Bn | 18.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.11 Bn | 124.26 Bn | 2.84 Bn | -66.70 Mn |
| 4 | Regeneron Pharmaceuticals | 82.51 Bn | 74.52 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.69 Bn | 56.50 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.62 Bn | 49.48 Bn | 52.00 Mn | -8.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.14 Bn | 30.84 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.29 Bn | 30.01 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.09 Bn | 30.09 Bn | 1.16 Mn | 7.11 Mn |
| 10 | TAO Synergies | 30.79 Mn | 30.79 Mn | - | -47,152.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -47,152.00 |
| Mar 31, 2026 | -228,996.00 |
| Dec 31, 2025 | 225,673.00 |
| Sep 30, 2025 | 628,754.00 |
| Jun 30, 2025 | 206,715.00 |
| Mar 31, 2025 | -203,106.00 |
| Dec 31, 2024 | 30,937.00 |
| Sep 30, 2024 | -188,980.00 |
| Jun 30, 2024 | 236,425.00 |
| Mar 31, 2024 | -205,728.00 |
| Dec 31, 2023 | 230,415.00 |
| Sep 30, 2023 | -224,929.00 |
| Jun 30, 2023 | 83,246.00 |
| Mar 31, 2023 | -304,305.00 |
| Dec 31, 2022 | 176,816.00 |
| Sep 30, 2022 | 202,524.00 |
| Jun 30, 2022 | -120,484.00 |
| Mar 31, 2022 | -895,156.00 |
| Dec 31, 2021 | 361,131.00 |
| Sep 30, 2021 | 287,212.00 |